BLTE
Belite Bio, Inc
Healthcare · Biotechnology · NCM
$143.35
Data: 2026-05-18
✓ ETHICAL PASS
WEAK MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$5.7B
Total market value of the company
0.00
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About Belite Bio, Inc
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% PASS
Debt must be below 33% of total assets
Cash Ratio
8.6% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
AVOID
Overall assessment combining ethics, valuation, and quality
Ethical Score
N/A
Valuation Score
16.5
Quality Score
20.0
Combined
29.6
Trading at $143, 1114% above fair value of $12. Passes all ethical screens.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
77.4%
Historical annualised return based on price data
Days in State
59
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-07 | MATA NATHAN L. | Officer | 666 | $102,039 | |
| 2026-05-06 | MATA NATHAN L. | Officer | 1,000 | $153,839 | |
| 2026-05-05 | MATA NATHAN L. | Officer | 1,000 | $155,502 | |
| 2026-05-04 | MATA NATHAN L. | Officer | 1,000 | $155,636 | |
| 2026-05-01 | MATA NATHAN L. | Officer | 1,000 | $155,778 | |
| 2026-04-30 | MATA NATHAN L. | Officer | 1,000 | $156,973 | |
| 2026-04-29 | MATA NATHAN L. | Officer | 1,000 | $155,817 | |
| 2026-04-28 | MATA NATHAN L. | Officer | 1,000 | $159,162 | |
| 2026-04-27 | MATA NATHAN L. | Officer | 1,000 | $162,641 | |
| 2026-04-24 | MATA NATHAN L. | Officer | 1,000 | $159,556 |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-18